1. Poor compliance: The hidden risk factor

   • John C. LaRosa

   Invited Commentary Pages: 1 - 4

2. Web alert

   • Robert Chilton

   Announcement Pages: 5 - 6

3. Literature alert

   • David T. Nash

   Announcement Pages: 7 - 8

4. Lipid modulation and atherosclerotic events: Extending the clinical spectrum with fibrates and statins

   • Evan A. Stein

   Clinical Trials Review Pages: 11 - 13

5. Does differing metabolism by cytochrome P450 have clinical importance?

   • Michael H. Davidson

   OriginalPaper Pages: 14 - 19

6. Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins?

   • Agostino Faggiotto
   • Rodolfo Paoletti

   OriginalPaper Pages: 20 - 25

7. Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk

   • MacRae F. Linton
   • Sergio Fazio

   OriginalPaper Pages: 29 - 35

8. Mechanism of action of niacin on lipoprotein metabolism

   • Vaijinath S. Kamanna
   • Moti L. Kashyap

   OriginalPaper Pages: 36 - 46

9. Probucol

   • Karl D. Pfuetze
   • Carlos A. Dujovne

   OriginalPaper Pages: 47 - 57

10. Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol

    • Patrick H. Bowen
    • John R. Guyton

    OriginalPaper Pages: 58 - 63

11. Niacin dosing: Relationship to benefits and adverse effects

    • David M. Capuzzi
    • John M. Morgan
    • Charles M. Intenzo

    OriginalPaper Pages: 64 - 71

12. Complete and selective estrogenic effects on lipids and cardiovascular disease

    • Stefania Lamon-Fava

    OriginalPaper Pages: 72 - 75

13. Lipophilic calcium antagonists in antiatherosclerotic therapy

    • Stefano Bellosta
    • Franco Bernini

    OriginalPaper Pages: 76 - 81